α1抗トリプシン欠損症増強療法の世界市場レポート 2025年

α1抗トリプシン欠損症増強療法市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で24億7,000万米ドルに成長します。予測期間の成長は、遠隔医療と遠隔モニタリング、精密医療、遺伝子治療の開発に起因しています。予測期間の主な動向には、長期安全性・有効性データ、患者中心のケアモデル、遠隔リハビリテーションプログラム、個別化投与レジメンなどが含まれます。

α1抗トリプシン欠損症増強療法市場は、呼吸器疾患の有病率の上昇により成長を遂げています。呼吸器疾患は、肺や呼吸器系に影響を与え、呼吸困難や肺機能の低下につながる様々な症状を包括します。α1抗トリプシン欠損症増強療法は、α-1抗トリプシン欠乏症患者の不足タンパク質を補うことで、呼吸器疾患への対応に重要な役割を果たしています。この治療法は、肺のプロテアーゼ・アンチプロテアーゼ活性のバランスを回復させ、過剰な好中球エラスターゼ活性によるダメージから肺組織を守り、炎症を抑えます。2023年3月現在の米国疾病予防管理センターのデータによると、2022年に米国で報告された結核患者は8,300人で、2021年に記録された7,874人から増加しています。このように、呼吸器疾患の有病率の増加は、α1抗トリプシン欠損症増強療法市場の主要な促進要因です。

α1抗トリプシン欠損症増強療法市場の成長予測は、臨床試験数の増加に関連しています。臨床試験とは、介入に関する特定の疑問を解決するために、ヒトを対象として実施される重要な生物医学的または行動学的調査研究のことで、新しい治療や、さらなる評価と比較が必要な既知の介入を含みます。これらの臨床試験は、α-1アンチトリプシン欠乏症（AATD）治療のための新規治療法や薬剤の開発・承認において非常に重要な意味を持っています。臨床試験の急増は、新たなAATD治療法の開拓に対する関心の高まりを意味し、市場により効果的な治療法の導入につながる可能性があります。例えば、2023年5月時点のXtalksのレポートによると、ClinicalTrials.govに登録された臨床試験は452,604件でした。この数は、2021年初頭に記録された365,000件以上の登録試験から顕著な増加を示しています。その結果、臨床試験の急増がα1抗トリプシン欠損症増強療法市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界α1抗トリプシン欠損症増強療法PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のα1抗トリプシン欠損症増強療法市場：成長率分析
• 世界のα1抗トリプシン欠損症増強療法市場の実績：規模と成長, 2019-2024
• 世界のα1抗トリプシン欠損症増強療法市場の予測：規模と成長, 2024-2029, 2034F
• 世界α1抗トリプシン欠損症増強療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のα1抗トリプシン欠損症増強療法市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• グラシア
• アララスト国立公園
• プロラスチンC
• ゼマイラ
• レスプレザ
• 世界のα1抗トリプシン欠損症増強療法市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射
• 吸入
• 世界のα1抗トリプシン欠損症増強療法市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー

第7章 地域別・国別分析

• 世界のα1抗トリプシン欠損症増強療法市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のα1抗トリプシン欠損症増強療法市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• α1抗トリプシン欠損症増強療法市場：競合情勢
• α1抗トリプシン欠損症増強療法市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Baxter International Inc.
• CSL Limited
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Grifols S.A.
• BioMarin Pharmaceutical Inc.
• LFB Group
• Octapharma AG
• Arrowhead Pharmaceuticals Inc.
• Kamada Ltd.
• Krystal Biotech Inc.
• Intellia Therapeutics Inc.
• Mereo BioPharma Group PLC
• Protalix BioTherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• α1抗トリプシン欠損症増強療法市場2029：新たな機会を提供する国
• α1抗トリプシン欠損症増強療法市場2029：新たな機会を提供するセグメント
• α1抗トリプシン欠損症増強療法市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Alpha-1 antitrypsin deficiency augmentation therapy is a medical intervention that involves the infusion of purified alpha-1 antitrypsin protein into individuals with deficient levels. This therapy is designed to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes, with the goal of slowing the progression of emphysema and enhancing lung function in affected patients.

The primary products used in alpha-1 antitrypsin deficiency augmentation therapy include Glassia, Aralast NP, Prolastin C, Zemaira, and Respreeza. Glassia, for instance, is a medication comprising human Alpha1-Proteinase inhibitors (Alpha1-PI) and is indicated for the treatment of lung disease (emphysema) in adults with severe alpha1-antitrypsin (Alpha1) deficiency. These therapeutic products are administered through various methods, including oral, injection, and inhalation, and are typically provided in healthcare settings such as hospitals, specialty clinics, and more.

The alpha-1 antitrypsin deficiency augmentation therapy market research report is one of a series of new reports from The Business Research Company that provides alpha-1 antitrypsin deficiency augmentation therapy market statistics, including alpha-1 antitrypsin deficiency augmentation therapy industry global market size, regional shares, competitors with an alpha-1 antitrypsin deficiency augmentation therapy market share, detailed alpha-1 antitrypsin deficiency augmentation therapy market segments, market trends and opportunities and any further data you may need to thrive in the alpha-1 antitrypsin deficiency augmentation therapy industry. This alpha-1 antitrypsin deficiency augmentation therapy market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.

The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.

The alpha-1 antitrypsin deficiency augmentation therapy market is experiencing growth due to the rising prevalence of respiratory diseases. Respiratory diseases encompass a range of conditions affecting the lungs and the respiratory system, leading to breathing difficulties and compromised lung function. Alpha-1 antitrypsin deficiency augmentation therapy plays a crucial role in addressing respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. This therapy restores the balance of protease-antiprotease activity in the lungs, shielding lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. Notably, according to data from the Centers for Disease Control and Prevention as of March 2023, there were 8,300 reported cases of tuberculosis (TB) in the United States in 2022, marking an increase from the 7,874 cases recorded in 2021. As such, the growing prevalence of respiratory diseases is a key driver for the alpha-1 antitrypsin deficiency augmentation therapy market.

Anticipated growth in the alpha-1 antitrypsin deficiency augmentation therapy market is linked to the escalation in the number of clinical trials. Clinical trials represent essential biomedical or behavioral research studies conducted with human participants to address specific questions about interventions, encompassing new treatments and known interventions necessitating further evaluation and comparison. These trials hold immense significance in the development and approval of novel therapies and medications for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The surge in clinical trials signifies a heightened interest in the development of fresh AATD therapies, potentially leading to the introduction of more effective treatments in the market. For instance, a report by Xtalks as of May 2023 reveals that there were 452,604 clinical studies registered on ClinicalTrials.gov. This number represents a notable increase from the over 365,000 registered trials documented in early 2021. Consequently, the upsurge in clinical trials is a driving force behind the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Prominent companies operating in the acute respiratory distress syndrome (ARDS) market are placing their focus on the development of innovative therapies, particularly those rooted in recombinant technology-based drug development, to maintain their competitive position in the market. Recombinant DNA technology is utilized to create therapeutic pharmaceuticals via recombinant technology-based drug development. This approach involves modifying the DNA of living organisms to synthesize specific proteins. As an illustration, in March 2022, Inhibrx Inc., a biotechnology company based in the United States, announced the U.S. Food and Drug Administration's (FDA) grant of orphan drug designation to INBRX-101 for the treatment of alpha-1 antitrypsin deficiency (AATD). INBRX-101 represents a recombinant human AAT-Fc fusion protein designed for potential once-monthly dosing to safely achieve and maintain AAT levels comparable to those found in healthy individuals.

In January 2023, GlaxoSmithKline PLC, a United Kingdom-based pharmaceutical and biotechnology company, made a significant investment by acquiring an 11% stake in Wave Life Sciences Ltd. for $50 million. This strategic move aims to leverage GSK's expertise in human genetics, global development, and commercial capabilities in collaboration with Wave's proprietary discovery and drug development platform, PRISMTM. The objective is to expedite the progress of oligonucleotide therapeutics for genetically determined diseases, including the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Wave Life Sciences Ltd. is a clinical-stage RNA medicine company based in the United States, specializing in the development of drugs for AATD and other conditions.

Major companies operating in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alpha-1 antitrypsin deficiency augmentation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alpha-1 antitrypsin deficiency augmentation therapy market consists of sales of Fazirsiran and RNA interference (RNAi) therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha-1 antitrypsin deficiency augmentation therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alpha-1 antitrypsin deficiency augmentation therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha-1 antitrypsin deficiency augmentation therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza
• 2) By Route Of Administration: Oral; Injection; Inhalation
• 3) By End User: Hospitals; Specialty Clinics; Other End Users
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Characteristics

3. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends And Strategies

4. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Rate Analysis
• 5.4. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Total Addressable Market (TAM)

6. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segmentation

• 6.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glassia
• Aralast NP
• Prolastin C
• Zemaira
• Respreeza
• 6.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• Inhalation
• 6.3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Speciality Clinics
• Other End Users

7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Regional And Country Analysis

• 7.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 8.1. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 9.1. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 9.2. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 10.1. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 11.1. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 11.2. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 12.1. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 13.1. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 14.1. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 14.2. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 15.1. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 15.2. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 16.1. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 17.1. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 18.1. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 19.1. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 20.1. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 21.1. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 21.2. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 22.1. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 23.1. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 23.2. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 24.1. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 24.2. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 25.1. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 25.2. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 26.1. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 26.2. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 27.1. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 28.1. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 28.2. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

• 29.1. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
• 29.2. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Landscape And Company Profiles

• 30.1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Landscape
• 30.2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Baxter International Inc.
• 31.3. CSL Limited
• 31.4. Biogen Inc.
• 31.5. Vertex Pharmaceuticals Incorporated
• 31.6. Grifols S.A.
• 31.7. BioMarin Pharmaceutical Inc.
• 31.8. LFB Group
• 31.9. Octapharma AG
• 31.10. Arrowhead Pharmaceuticals Inc.
• 31.11. Kamada Ltd.
• 31.12. Krystal Biotech Inc.
• 31.13. Intellia Therapeutics Inc.
• 31.14. Mereo BioPharma Group PLC
• 31.15. Protalix BioTherapeutics Inc.

32. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

34. Recent Developments In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

35. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market High Potential Countries, Segments and Strategies

• 35.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer